Indraprastha Medical Corporation Limited

(Indraprastha Apollo Hospitals, New Delhi - A Joint Sector Venture of Govt. of Delhi)

Regd. Office: Sarita Vihar, Delhi-Mathura Road, New Delhi-110 076 (India)

Corporate Identity Number: L24232DL1988PLC030958

Phones: 91-11-26925858, 26925801, Fax: 91-11-26823629 E-mail: imcl@apollohospitals.com, Website: apollohospdelhi.com

Ref: IMCL/CS/BM/2021

8th February, 2021

The Manager Listing Department BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai, Maharashtra - 400001 Scrip Code: 532150

The Manager
Listing Department
National Stock Exchange of India Limite
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra East,
Mumbai, Maharashtra – 400051
Symbol: INDRAMEDCO

Re: Outcome of the Board Meeting - Unaudited Financial Results for the quarter & nine months ended 31st December, 2020

Dear Sir,

The Board of Directors of the Company, at their meeting held on 8th February, 2021, have approved the Unaudited Financial Results for the quarter and nine months ended 31st December, 2020.

We are enclosing herewith a copy of the Unaudited Financial Results for the quarter and nine months ended 31st December, 2020, along with a copy of the Limited Review Report by the Auditors.

The Board meeting started at 12.15 p.m. and ended at 02:40 p.m.

This is for your information and record.

Thanking You,

Sincerely Yours,

For Indraprastha Medical Corporation Limited

Priya Ranjan

AVP - Corporate Affairs & Legal

(Company Secretary & Compliance Officer)

Encl. as above

S.N. Dhawan & CO LLP

Chartered Accountants

421, Il Floor, Udyog Vihar Phase IV, Gurugram, Haryana 122016, India

Tel: +91 124 481 4444

Limited Review Report on Unaudited Quarterly and Year to date Results

To the Board of Directors of Indraprastha Medical Corporation Limited

- 1. We have reviewed the accompanying statement of unaudited financial results of Indraprastha Medical Corporation Limited ("the Company") for the quarter ended 31 December 2020 and year to date results for the period 01 April 2020 to 31 December 2020 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India ("the SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant Rules issued thereunder; and other accounting principles generally accepted in India. Our responsibility is to issue a conclusion on the Statement based on our review.
- 2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Emphasis of Matter

4. We draw attention to Note 3 of the Statement which describes the impact of Covid-19 pandemic on the Company's Operations and the management's assessment of assets, trade receivables and inventories of the Company. Our conclusion is not modified in respect of this matter.

For S.N. Dhawan & Co LLP

Chartered Accountants

Firm Registration No.: 000050N/N500045

& MAN

Rajeev K Saxena

Partner

Membership No.: 077974

UDIN No.: 21077974AAAABB3842


Place: New Delhi

Date: February 08, 2021

INDRAPRASTHA MEDICAL CORPORATION LIMITED

Registered office : Sarita Vihar, Delhi Mathura Road, New Delhi - 110076

Corporate Identity Number: L24232DL1988PLC030958 Phone: 91-11-26925858, 26925801, Fax: 91-11-26823629





Statement of Unaudited Financial Results for the Quarter and Nine-months ended 31st December, 2020

Amount (Rs. in million)

S. No.	Particulars	Quarter ended			Nine-months ended		Year ended
		31.12.2020	30.09.2020	31.12.2019	31.12.2020	31.12.2019	31.03.2020
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	1800.10	1410.88	2104.27	4153.13	6302.64	8307.68
2	Other Income	1.23	1.22	0.81	4.48	5.33	6.87
3	Total income	1801.33	1412.10	2105.08	4157.61	6307.97	8314.55
4	Expenses	I SOUTH PLAN.					
	a) Cost of material consumed	339.37	263.80	365.84	798.55	1144,58	1516.07
	b) Employee benefits expense	492.97	495.28	537.10	1502.29	1583.80	2139.30
	c) Professional charges to doctors	382.01	292.77	503.80	883.77	1534,96	2007.93
	d) Finance cost	8.46	8.54	14.49	24.19	46.82	59.17
	e) Depreciation and amortisation expense	83.97	82.90	83.81	248.96	247.25	329.69
	f) Other expenses	326.11	264.50	461.12	865.33	1350.67	1780.47
	Total expenses	1632.89	1407.79	1966,16	4323.09	5908.08	7832.63
5	Profit before exceptional items and tax	168.44	4.31	138.92	(165.48)	399.89	481.92
6	Exceptional items	í.,	-			-	
7	Profit before tax (PBT)	168.44	4.31	138.92	(165.48)	399.89	481.92
8	Tax expense						
	Current tax	- 2		7.54		78.85	109.41
	Deferred tax	48.59	(0.07)	24.60	(37.81)	(50.25)	(63.73)
9	Profit for the period after tax (PAT)	119.85	4.38	106.78	(127.67)	371.29	436.24
10	Other comprehensive income				,		
	a). (i) Items that will not be reclassified to profit or loss	1.64	21.35	(1.67)	27.45	(15.22)	(27.54)
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	(0.42)	(5.37)	0.57	(6.91)	5.32	7.06
	Total other comprehensive income, (Net of tax expenses)	1,22	15.98	(1.10)	20.54	(9.90)	(20.48)
11	Total comprehensive income for the period	121.07	20.36	105.68	(107.13)	361.39	415.76
12	Paid-up equity share capital (Face value Rs. 10/- each)	916.73	916.73	916.73	916.73	916.73	916.73
13	Reserves (excluding Revaluation Reserves) as shown in the audited balance sheet of previous year			1000000		110000000000000000000000000000000000000	1761.27
14	Earnings per share Basic and Diluted (Rs.) - Not Annualised	1,31	0.05	1.16	(1.39)	4.05	4.76

Notes:

- The above financial results were reviewed by the Audit Committee and have been approved by the Board of Directors at their meeting held on 8th February, 2021.
- The Company operates in a single segment i.e. Healthcare and hence, does not have any additional disclosures to be made under Ind AS 108 on Operating Segments.
- 3. The outbreak of COVID-19 pandemic and consequent lockdown has impacted regular business operations due to restrictions on international and domestic travel. Based on the internal & external information upto the date of approval of these financial statements, the company expects to recover the carrying amount of its assets, trade receivables & inventories. Further, the management do not anticipate any issues at all related to the Company's ability to undertake borrowings or service debt given its comfortable liquidity position and its ability to access debt at competitive levels. The Company will continue to monitor future economic conditions and assess its impact on its financial statements.
- 4. The Directorate General of Health Services (DGHS) of Govt, of NCT Delhi, based on the recommendations of the Expert Committee of Ministry of Health and Family Welfare, Govt, of India, which was constituted in compliance of the Hon'ble Supreme Court judgment dated 29th January, 2016 in WP (C) 527/2011 in the matter of Trained Nurses Association of India Vs. Union of India & Ors, had issued an order dated 25th June, 2018, which inter-alia provides that in case of more than 200 bedded hospitals, salary given to private nurses should be at par with the salary of the nurses in the State Government hospitals.
 - The Association of Healthcare Providers of India (AHPI) of which the Company is a member had filed a writ petition in the High Court of Delhi challenging the order issued by DGHS. The Hon'ble High Court of Delhi upheld the order dated 25th June, 2018, issued by DGHS.
 - AHPI has filed an LPA (Letter Patent Appeal) before the division bench of the Hon'ble High Court. The division bench has admitted the LPA and the matter is sub-judice. In case, the order issued by DGH5 of Govt. of NCT of Delhi is to be implemented, it shall have a major adverse impact on the financials of the Company.
- The Code on Social Security, 2020 has been enacted, which could impact the contributions by the company towards Provident Fund and Gratuity.The effective date from which the changes are applicable is yet to be notified. Impact if any, of the change will be assessed and accounted in period of notification of relevant provisions.
- Previous year/period figures have been regrouped / rearranged wherever necessary.

Place: New Delhi Date: 8th February, 2021



P. Shivakumar (Managing Director)